GSK, the British pharma group, has struck a $1.4bn deal to acquire Anglo-American biotech Aiolos Bio, which makes respiratory medicines.
The acquisition will give GSK access to a treatment entering mid-stage trials that it hopes will broaden its range of asthma products.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased